Pronutria Adds Industry Leaders to its Board of Directors

CAMBRIDGE, Mass., Dec. 8, 2014 /PRNewswire/ -- Pronutria Inc., which is developing novel oral biologics to restore cellular homeostasis in a range of serious medical conditions, announced today that industry veterans Peter Barton Hutt, Senior Counsel at Covington & Burling and former chief counsel of the FDA; Dr. Stephen Hoge, Senior Vice President, Corporate Development and New Drug Concepts for Moderna Therapeutics; and Dr. John Mendlein, Executive Chairman and CEO of aTyr Pharma and former CEO of Adnexus Therapeutics, have joined the Board of Directors. 

"We are thrilled to add these industry veterans to our Board, bringing tremendous expertise, decades of experience and even more creativity to the company," said Dr. Noubar Afeyan, Pronutria Co-Founder and Chairman and Managing Partner and CEO of Flagship Ventures. "They add to the outstanding leadership foundation we have put in place at Pronutria."

Peter Hutt brings significant regulatory experience to Pronutria, specializing in food and drug law at Covington & Burling.  From 1971 to 1975 he was Chief Counsel for the Food and Drug Administration. Mr. Hutt has been a member of the Institute of Medicine of the National Academy of Sciences (NAS) since it was formed in 1971.

Stephen Hoge, M.D., provides leading strategy, corporate development, and medical experience to Pronutria.  He is currently Senior Vice President, Corporate Development and New Drug Concepts for Moderna Therapeutics. Prior to Moderna, Stephen was a partner at McKinsey & Company and a leader in the firm's Healthcare and Corporate Finance practices.

John Mendlein, Ph.D., J.D., brings a deep and proven entrepreneurial background to Pronutria.  He is Executive Chairman and CEO of aTyr Pharma and Vice Chairman of Fate Therapeutics. He previously served as CEO of Adnexus Therapeutics, a Flagship VentureLabs-founded pioneer of a new class of protein therapeutics, which was acquired by Bristol-Myers Squibb Company for $505 million. 

"These important additions to our Board of Directors bring a blend of regulatory, strategic and R&D leadership experience to Pronutria," said Robert Connelly, CEO of Pronutria.  "Our Board of Directors includes some of the most prolific entrepreneurs, strategists and deal makers in the industry and we are pleased to have them on the team and look forward to their contributions as we move to our next phase of growth." 

About Pronutria

Pronutria is developing novel oral biologics to restore cellular homeostasis in a range of serious medical conditions.  Using a proprietary platform, Pronutria is creating oral biologics to address health conditions caused or worsened by imbalances in amino acids that lead to harmful changes in cellular homeostasis. Pronutria's products improve health by activating specific physiologic events that focus on amino acid imbalances and act to restore cellular homeostasis.  Founded by the Flagship Ventures innovation foundry, VentureLabs, Pronutria has built a proprietary library containing over one billion polypeptides from which it selects candidates delivering amino acids with great precision and reproducibility.  For more information, please visit www.pronutria.com.

Contact:

For Pronutria:  Emily Rossi
Ruder Finn
212.593.6431
[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pronutria-adds-industry-leaders-to-its-board-of-directors-300004410.html

SOURCE Pronutria

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED